ProteoNic
ProteoNic BV is a Dutch private biotech founded in 2004 that licenses its proprietary 2G UNic® mammalian expression vector technology to biopharmaceutical manufacturers to increase yields and reduce costs of monoclonal antibody and biologic production.
- Company typePrivate
- Founded2004
- HeadquartersLeiden, Netherlands
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What ProteoNic does
ProteoNic BV is a Dutch privately held biotechnology company founded in 2004 and headquartered in Leiden, Netherlands, with 11–50 employees. The company develops and licenses proprietary vector technology for mammalian cell-based biomanufacturing, anchored by its flagship 2G UNic® platform — a high-performance expression vector system engineered to enhance protein expression and productivity in mammalian production systems used to manufacture monoclonal antibodies and other biologics.
ProteoNic operates as a technology licensor rather than a drug developer, generating revenue through licensing arrangements with biotechnology and pharmaceutical manufacturers. These deals typically combine upfront fees, development milestones, and royalties on commercialized products. Its customer base historically consists of biopharmaceutical manufacturers seeking higher-yield, lower-cost production of therapeutic biologics; in November 2025 the company broadened its footprint by licensing 2G UNic® to Ginkgo Bioworks for use in a BARDA-funded Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) project valued at up to $22.2 million, targeting scalable manufacturing of anti-filovirus monoclonal antibodies (Ebola and Sudan virus) for pandemic preparedness.
The company functions as an embedded component supplier within larger biomanufacturing workflows and multi-organization consortia, positioning 2G UNic® as a foundational expression technology that partners integrate into their cell line and process development pipelines. Revenue is not publicly disclosed, and the firm has no parent company, subsidiaries, or public listing.
ProteoNic firmographics
Firmographics- Name
- ProteoNic
- Legal name
- ProteoNic BV
- Website
- https://proteonic.nl
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ProteoNic BV is a Dutch private biotech founded in 2004 that licenses its proprietary 2G UNic® mammalian expression vector technology to biopharmaceutical manufacturers to increase yields and reduce costs of monoclonal antibody and biologic production.
- Ownership category
- akta.pro rank
ProteoNic industry classification
Industry- Product category
- Biopharmaceutical Manufacturing Technology
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
- akta.pro secondary industries
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD), Bioprocess Consumables & Reagents (resins, membranes, media components, buffers) (HLAAAJAI)
Keywords
Where ProteoNic is headquartered
LocationHeadquarters
- HQ city
- Leiden
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
ProteoNic business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Technology Licensing: ProteoNic generates revenue by licensing its proprietary 2G UNic® vector technology to biotech and pharmaceutical companies for use in biomanufacturing. The licensing arrangements likely include upfront fees, milestone payments, and potentially royalties tied to development and commercial success.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
ProteoNic product offering
Product offeringCore offering
ProteoNic licenses its proprietary 2G UNic® vector technology to biotech and pharmaceutical companies to enhance protein expression and productivity in mammalian cell-based production systems. The technology is applied primarily in biomanufacturing of monoclonal antibodies and other biologics, enabling higher yields, lower production costs, and improved scalability. Revenue is generated through licensing arrangements, including upfront fees, milestone payments, and royalties tied to development and commercial success.
Product overview
ProteoNic offers a single unified technology platform built around its proprietary 2G UNic® vector technology. This flagship product is a high-performance expression vector system designed to significantly enhance protein expression and productivity in mammalian cell systems, enabling faster, scalable, and cost-effective biomanufacturing of biologics including monoclonal antibodies for therapeutic applications.
Differentiator
Problem solved
Functional benefit
Products and services
- 2G UNic® ProteoNic's proprietary high-performance vector technology designed to enhance protein expression and productivity in mammalian production systems for biopharmaceutical manufacturing, particularly for monoclonal antibody production. Licensed to biotech and pharmaceutical companies for integration into their biomanufacturing workflows.
Quantifiable outcome
- Up to $22.2 million BARDA-funded project secured through technology licensing partnership
Companies that use ProteoNic
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
ProteoNic technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
ProteoNic partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Ginkgo BioworkscoreProteoNic licensed its proprietary 2G UNic® vector technology to Ginkgo Bioworks for use in a BARDA-funded project worth up to $22.2 million through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium). The project aims to develop cost-effective monoclonal antibody manufacturing for filovirus infections including Ebola and Sudan Virus.
- Advanced BioScience LaboratoriescorePartner in the BARDA-funded BioMaP-Consortium project led by Ginkgo Bioworks, focused on developing biomanufacturing approaches for monoclonal antibodies against filoviruses. Part of a multi-partner team working to scale production of anti-filovirus antibody cocktails.
- Isolere Bio by DonaldsoncorePartner in the BARDA-funded BioMaP-Consortium project led by Ginkgo Bioworks, contributing to the development of new technologies to streamline antibody production for filoviruses such as Ebola.
- NeuImmunecorePartner in the BARDA-funded BioMaP-Consortium project led by Ginkgo Bioworks, collaborating on the development of biomanufacturing innovations for monoclonal antibodies against filoviruses.
Scale indicators1 record
Recent moves4 records
Expansion highlights4 records
ProteoNic competitors and assessment
Company assessmentBroad incumbents
- Lonza Biologics: Lonza is a global CDMO with proprietary expression platforms (e.g., GS Xceed) for mammalian biologics manufacturing. Overlaps with ProteoNic on expression-vector IP but operates at vastly broader scale across the full CDMO value chain.
- Cytiva: Cytiva supplies bioprocessing technologies, media, and expression systems used in mammalian cell-based biologics production. Adjacent incumbent serving the same downstream biomanufacturing customers as ProteoNic with a much wider portfolio.
- Sartorius: Sartorius provides bioprocessing equipment, consumables, and cell-line development services for biologics manufacturers. Comparable end-customers and category overlap, but at much broader scale and as a public-listed equipment/platform incumbent.
- Thermo Fisher Scientific (Patheon/CDMO and Gibco): Through its Gibco bioproduction and CDMO arms, Thermo Fisher offers cell line development, media, and expression technologies for mAb manufacturing. A broad incumbent serving the same biologics manufacturing ecosystem as ProteoNic.
Direct peers
- ATUM (formerly DNA2.0): ATUM provides synthetic biology tools, gene synthesis, and protein expression optimization platforms for biologics developers. Comparable to ProteoNic as a protein-engineering-focused platform targeting biologics manufacturing yield improvements.
- Selexis (JSR Life Sciences): Selexis offers proprietary cell line and expression technologies (SUREtechnology) for monoclonal antibody and recombinant protein production in mammalian systems. Directly comparable to ProteoNic as a vector/cell-line IP licensor serving biopharma manufacturers.
Regional players
- WuXi Biologics: WuXi Biologics is a leading Asia-based biologics CDMO with proprietary expression and manufacturing platforms. Comparable in serving biologics manufacturers with proprietary IP, but predominantly serving Asia-based and global innovator clients from China-based operations.
- Samsung Biologics: Samsung Biologics is a Korea-based large-scale biologics CDMO with its own cell-line and expression capabilities. Compares to ProteoNic in addressing biologics manufacturing needs but operates at the scale of a global CDMO primarily out of Asia.
Emerging players
- Bota Bio: Bota Bio is a synthetic biology company developing biomanufacturing platforms and engineered strains for sustainable production of proteins and other biologics. Comparable as an emerging platform player targeting biologics manufacturing with synthetic biology-driven approaches.
Others
- Ginkgo Bioworks: Ginkgo Bioworks is ProteoNic's anchor licensing partner and a leading synthetic biology platform that codesigns cell engineering programs for biopharma customers. Listed as OTHERS because it is a partner/ecosystem enabler rather than a direct competitor, but highly relevant to ProteoNic's go-to-market motion.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
ProteoNic social profiles
Digital presenceProteoNic financial estimates
Financial estimateRevenue estimate
Valuation estimate
ProteoNic leadership team
Management profileNumber of profiles
Profiles1 record
ProteoNic funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ProteoNic M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ProteoNic
What does ProteoNic do?
ProteoNic licenses its proprietary 2G UNic® vector technology to biotech and pharmaceutical companies to enhance protein expression and productivity in mammalian cell-based production systems. The technology is applied primarily in biomanufacturing of monoclonal antibodies and other biologics, enabling higher yields, lower production costs, and improved scalability. Revenue is generated through licensing arrangements, including upfront fees, milestone payments, and royalties tied to development and commercial success.
Is ProteoNic a public or private company?
ProteoNic is a private company. It is classified as unknown and is currently operating.
When was ProteoNic founded?
ProteoNic was founded in 2004. It employs 11 to 50 people.
Where is ProteoNic based?
ProteoNic is headquartered in Leiden, Netherlands, in the Europe region.
How does ProteoNic make money?
One revenue line is on record: technology Licensing.
Who are ProteoNic's main competitors?
Broad incumbents on record are Lonza Biologics, Cytiva, Sartorius and Thermo Fisher Scientific (Patheon/CDMO and Gibco). Direct peers are ATUM (formerly DNA2.0) and Selexis (JSR Life Sciences). Regional players are WuXi Biologics and Samsung Biologics. Bota Bio is listed as an emerging player. Ginkgo Bioworks is listed as an others.
Does ProteoNic have an API?
No public API is recorded for ProteoNic.
What industry is ProteoNic in?
ProteoNic's product category is Biopharmaceutical Manufacturing Technology. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 325414 and its SIC code is 2836.